Trial Profile
6-Month, Multicenter, Randomized, Open-label, 2-Arm, Parallel-group Study Comparing the Efficacy and Safety of a New Formulation of Insulin Glargine and Lantus Injected Once Daily in Children and Adolescents Age 6 - 17 Years With Type 1 Diabetes Mellitus With a 6-month Safety Extension Period
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 23 Dec 2021
Price :
$35
*
At a glance
- Drugs Insulin glargine (Primary)
- Indications Type 1 diabetes mellitus
- Focus Registrational; Therapeutic Use
- Acronyms EDITION JUNIOR
- Sponsors Sanofi
- 19 May 2020 Results published in the Diabetes Care
- 06 Feb 2020 According to a Sanofi media release, the European Commission approved the expansion of the indication for Toujeo in the European Union to include the treatment of diabetes in adolescents and children (6 years and older) in January.
- 03 Nov 2019 According to a Sanofi media release, data from this trial were presented at the International Society for Pediatric and Adolescent Diabetes 45th Annual Conference in Boston, Massachusetts.